Atlas Trials

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Clinical trial NCT06540963 · RECRUITING

Trial details

NCT number
NCT06540963
Sponsor
Giselle Sholler
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroblastoma
Start date
2024-12-06
Primary completion
2030-12-01
Enrollment
98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.